Quotient Bio Adds $5M, Appoints New Corporate President
February 28, 2013
Quotient Biodiagnostics, a developer of transfusion diagnostics products and technology, has closed a $5 million round of financing from Paul Cowan, the company’s CEO, and Galen Partners, a VC firm based in Stamford, CT. The new equity will go toward the continued development of Quotient’s “next generation automation platform for transfusion diagnostics,” according to a press release. In conjunction with the deal, the company has announced the appointment of Ed Farrell as the corporate president responsible for this undertaking.